Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 4, Pages 1017-1025
Publisher
Oxford University Press (OUP)
Online
2012-11-15
DOI
10.1093/annonc/mds585
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial‡
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- Clinically relevant fatigue in recurrence-free prostate cancer survivors
- (2011) D. J. Storey et al. ANNALS OF ONCOLOGY
- Cabazitaxel for the treatment of prostate cancer
- (2011) Dirk PJ Michielsen et al. EXPERT OPINION ON PHARMACOTHERAPY
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- (2011) Roberto Pili et al. JOURNAL OF CLINICAL ONCOLOGY
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- The Impact of an Outpatient Palliative Care Consultation on Symptom Burden in Advanced Prostate Cancer Patients
- (2011) Sriram Yennurajalingam et al. JOURNAL OF PALLIATIVE MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer
- (2010) Jorge A. Garcia et al. CANCER
- Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer
- (2010) J. Hofland et al. CANCER RESEARCH
- A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations
- (2010) E. Efstathiou et al. CLINICAL CANCER RESEARCH
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- ASCPRO Recommendations for the Assessment of Fatigue as an Outcome in Clinical Trials
- (2010) Andrea M. Barsevick et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- From pathogenesis to prevention of castration resistant prostate cancer
- (2009) Helmut Bonkhoff et al. PROSTATE
- Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases
- (2008) Olav Lindqvist et al. European Journal of Oncology Nursing
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started